Lundberg Foundation Supports Breakthrough Research on Glycomes in Lung Cancer

In the multifaceted battle against cancer, Daniel Bojar's research stands out. Focusing on cancer-specific glycans, Bojar's groundbreaking project recently earned a SEK 4 million grant from the Lundberg Foundation. This timely funding will be channelled towards acquiring a top-tier mass spectrometer, adeptly enhancing AI-driven high-throughput glycomics using Bojar group’s bespoke software.

But what makes this project so riveting? Daniel Bojar, an assistant professor at the department of chemistry and molecular biology and a fellow at the Wallenberg center for molecular and translational medicine, aims to combine this high-tech spectrometer with the group's pioneering AI and deep learning methodologies. The outcome? A glycomics analysis system boasting unrivalled sensitivity and speed, the first of its kind in Sweden.

The analysis will focus on saliva samples from lung cancer patients, contrasting them with samples from mouse tumors and healthy controls. The objective is to pinpoint glycan structures uniquely expressed in lung cancer, potentially heralding a future of personalized treatments.

Partnerships are central to this venture, and Bojar's team collaborates extensively, not just within the University of Gothenburg, but with Chalmers University and Sahlgrenska University Hospital too.

The future of lung cancer research looks brighter, and the Lundberg Foundation's support is a beacon in this journey.